Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialRafael Rosell, Ana Drozdowskyj, Enric Carcereny et al.|The Lancet Oncology|2012Cited by 5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaWilliam D. Travis, David Yankelewitz, Kavita Garg et al.|Journal of Thoracic Oncology|2011Cited by 4.8k
Screening for Epidermal Growth Factor Receptor Mutations in Lung CancerRafael Rosell, Miquel Tarón, Teresa Morán et al.|New England Journal of Medicine|2009Cited by 2.4k
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patientsH. Cortés-Funes, Miquel Tarón, Carlos Gegúndez Gómez et al.|Annals of Oncology|2005Cited by 231
Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerS. Simonetti, Rafael Rosell|Journal of Translational Medicine|2010Cited by 94